Overview

A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin

Status:
RECRUITING

Trial end date:
2026-02-28

Target enrollment:

Participant gender:

Summary

This study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Degludec with or without Non-Insulin Antidiabetic Agents in subjects with Type 2 Diabetes Mellitus (T2DM) treated with basal insulin.

Phase:

PHASE3

Details

Lead Sponsor:

Gan & Lee Pharmaceuticals.

Treatments:

insulin degludec